Overview
Limiaoda develops AI small-molecule drugs, using AI to drive lead discovery and translation. It builds new drug pipelines based on AI, computational chemistry and medicinal chemistry, with a machine-learning lead discovery platform and proprietary optimized underlying algorithms. Its molecular docking platform efficiently screens drugs, shortening compound synthesis and screening, reducing testing and clinical R&D costs, and selecting compounds with stronger activity and better drug-like properties sooner.
Connected profiles
Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
立妙达是一家AI小分子药物研发商，致力于利用AI驱动小分子先导物研发和转化，打造基于人工智能、计算化学、药物化学等学科的全新药物研发管线，拥有基于机器学习技术的先导物研发平台，依托自主研发优化的底层算法，完成分子对接平台，高效地进行药物筛选，大大缩短了化合物合成及筛选所需的时间，节省测试及临床研发成本，更快选出活性较高且成药性更好的化合物。